EUCTR2014-003725-17-DE进行中（未招募）1 期
A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- MedImmune
- 入组人数
- 184
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Age 18-75 years
- •- Physician diagnosis of atopic dermatitis for > 1 year
- •- Atopic dermatitis involvement of = 15% body surface area
- •- EASI score of = 12
- •- SCORAD of = 25
- •- IGA score of = 3
- •- Effective birth control in line with protocol details
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 24
排除标准
- •- History of anaphylaxis following any biologic therapy
- •- Hepatitis B, C or HIV
- •- Pregnant or breastfeeding
- •- History of cancer
- •- Previous receipt of tralokinumab
研究者
相似试验
进行中（未招募）
不适用
Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults with Atopic DermatitisMedDRA version: 18.0Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic DermatitisEUCTR2014-003725-17-PLMedImmune Limited184
进行中（未招募）
1 期
A study to evaluate whether NEOD001 is safe and effective in subjects with light chain AL amyloidosis affecting the heart.ight chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, aggregated forms of light chains and insoluble,fibrillar deposits of abnormal AL protein (amyloid),in the tissues and organs. This can cause a range of symptoms and organ dysfunction including cardiac,renal,and hepatic dysfunction,gastrointestinal involvement and neuropathy and macroglossiaMedDRA version: 20.0Level: PTClassification code 10036673Term: Primary amyloidosisSystem Organ Class: 10021428 - Immune system disordersEUCTR2015-004318-14-DEProthena Therapeutics Limited129
进行中（未招募）
1 期
A Study of ALS-008176 in Infants and Children Hospitalized with RSVRespiratory Syncytial Virus InfectionMedDRA version: 20.1 Level: PT Classification code 10061603 Term: Respiratory syncytial virus infection System Organ Class: 10021881 - Infections and infestationsEUCTR2016-001641-79-GBJanssen-Cilag International NV120
招募中
1 期
A Phase 2b Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UCModerately to severely active ulcerative colitisMedDRA version: 20.1Level: LLTClassification code: 10045365Term: Ulcerative colitis Class: 10017947CTIS2022-500953-17-00Morphic Therapeutic Inc.319
进行中（未招募）
1 期
A double-blind, placebo-controlled Clinical Trial to evaluate the Safety and Efficacy of JNJ-64304500 in patients with Moderately to Severely Active Crohn’s DiseaseActive Crohn's DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2016-000634-21-DEJanssen-Cilag International NV654